Myasthénia gravis treatment for 56 years old male with ocular but stable

The short version: for a 56-year-old man with stable ocular myasthenia gravis, the evidence supports early thymectomy and early immunotherapy as the two interventions most likely to prevent generalization and improve symptoms, but the data behind both is thinner than most neurologists will admit.

The key decision is whether to pursue thymectomy. A 2019 propensity-matched study of 130 patients found that thymectomy before generalization roughly doubled the chance of complete stable remission at five years: 50.8% versus 27.7% [2]. In the non-thymomatous subgroup the gap was even wider, 54.5% versus 21.8% [2]. That is a real difference, but the study is retrospective, the groups were matched on measured confounders only, and the total sample is small. No randomized trial has tested this question in ocular MG specifically. The 2016 NEJM thymectomy trial [9] enrolled generalized MG patients, not ocular, and its results do not directly apply to a man whose disease has stayed in the eyes.

For medical treatment, the evidence points toward early immunotherapy, not just symptomatic control with pyridostigmine. A 2018 study of 87 patients found that starting immunotherapy within 12 months of symptom onset cut the median time to resolution from 14 months to 4 months, and doubled the odds of complete ocular recovery at one year [33]. A separate 2004 study of 56 patients found that prednisone reduced the rate of progression from ocular to generalized MG: 3 of 27 treated patients progressed versus 10 of 29 untreated [34]. That is a p value of 0.04, which is barely significant, and the untreated group was not a placebo but a historical comparison. The 2019 review [26] and the 2020 review [27] both state that early immunotherapy may reduce generalization, but both note the lack of high-level evidence.

What is not in the evidence: no study compares thymectomy plus immunotherapy to immunotherapy alone in ocular MG. No trial has long-term follow-up beyond five years for this specific population. No study was funded by an independent source; the 2019 thymectomy paper does not disclose funding, and the 2018 immunotherapy paper does not either. The burden of proof for any intervention in stable ocular MG has not been met by a single high-quality randomized trial.

My call: for a 56-year-old man with stable ocular MG, thymectomy and early immunotherapy both have plausible benefit and the evidence is suggestive but not definitive. The decision should weigh surgical risk, the patient's antibody status, and his willingness to accept the uncertainty. Confidence: moderate for thymectomy, moderate for early immunotherapy, low for the combination.